Nektar Therapeutics - NKTR STOCK NEWS

Nektar Therapeutics (Nasdaq: NKTR) presented promising preclinical data for NKTR-288 at the 2022 SITC Annual Meeting. NKTR-288, a PEG-conjugate of interferon gamma, demonstrated enhanced anti-tumor activity through upregulation of MHC Class I and PD-L1 in tumors, particularly in combination with anti-PD-1 or anti-PD-L1 therapies. The findings support further clinical evaluation of NKTR-288 as both a monotherapy and in combination treatments. The ongoing Phase 2 JAVELIN Bladder Medley study, led by Merck KGaA, aims to provide comparative efficacy data by end of 2024.

Nektar Therapeutics (Nasdaq: NKTR) has published preclinical data in Blood Advances on its product NKTR-255, a polymer-conjugated human IL-15. The findings show NKTR-255 induces CD8⁺ T cell and natural killer cell proliferation and enhances the efficacy of human CD19 CAR-T cells in lymphoma models. The company plans to progress into a Phase 2/3 clinical trial for NKTR-255 in combination with CAR-T therapies for relapsed or refractory diffuse large B-cell lymphoma. These promising results support ongoing research into NKTR-255's potential in cancer immunotherapy.

Nektar Therapeutics (Nasdaq: NKTR) reported its Q3 2022 financial results, showing a revenue of $23.6 million, down from $24.9 million in Q3 2021. Cash and marketable securities amounted to $546.4 million, supporting operations until mid-2025. Operating costs significantly decreased to $77.9 million from $138.5 million in the same quarter last year, primarily due to a reduction in R&D expenses. Net loss was $59.0 million, improved from $129.7 million year-over-year. The company highlights progress in its oncology and immunology pipeline, including positive data from NKTR-358.

Nektar Therapeutics (Nasdaq: NKTR) will announce its third quarter 2022 financial results on November 3, 2022, following the close of U.S. financial markets. CEO Howard Robin will host a conference call at 5:00 p.m. ET to discuss the results. Investors can access the press release and live audio webcast on the Nektar website, with a replay available until December 3, 2022.

Nektar focuses on oncology, immunology, and inflammatory diseases, boasting a robust R&D pipeline.

Nektar Therapeutics (NKTR) presented data from two Phase 1b studies of rezpegaldesleukin (LY3471851) for treating atopic dermatitis and psoriasis at the 2022 EADV Congress. The studies indicate a favorable safety profile and dose-dependent efficacy in patients with moderate-to-severe atopic dermatitis, with improvements observed up to 36 weeks post-treatment. In psoriasis patients, treatment led to sustained improvements in skin condition metrics. Partnered with Eli Lilly, further Phase 2 studies are planned for 2023, expanding the drug’s potential in addressing autoimmune diseases.

Nektar Therapeutics (Nasdaq: NKTR) announced the publication of preclinical data in Blood Advances on NKTR-255, highlighting its effects on natural killer (NK) cell function in multiple myeloma. The findings demonstrate NKTR-255's ability to enhance NK cell responses, increase NK activating receptor expression, and improve antibody-dependent cellular cytotoxicity (ADCC) in a humanized mouse model. These results support ongoing clinical studies, including a Phase 1 trial for NKTR-255 in relapsed or refractory cancers, showcasing its potential for synergistic treatment effects when combined with other therapies.

Nektar Therapeutics (NKTR) reported Q2 2022 financial results with revenues of $21.6 million, down from $28.3 million in Q2 2021. Operating costs rose to $174.4 million from $138.5 million. The company experienced a net loss of $159.1 million or $0.85 per share, compared to a loss of $125.5 million or $0.69 per share in the prior year. Cash and investments totaled approximately $628.2 million, expected to fund operations into 2025. Nektar is focusing on promising candidates like NKTR-358 and NKTR-255 to enhance shareholder value.

Nektar Therapeutics (NASDAQ: NKTR) will announce its Q2 financial results on August 4, 2022, post U.S. markets close. CEO Howard Robin will host a conference call at 5:00 p.m. ET to discuss results. Access to the press release and the live audio webcast is available through their website. The conference call will also have a replay available until September 4, 2022.

Nektar Therapeutics (NKTR) has promoted Jillian B. Thomsen to Senior Vice President & Chief Financial Officer. With over 30 years in finance, she previously served as SVP, Finance & Chief Accounting Officer since 2008. Her expertise in financial strategy will be crucial for Nektar's future, especially in overseeing accounting and capital market transactions. Gil Labrucherie, the outgoing CFO, has been with the company for 17 years and is leaving for a private biotechnology opportunity. This leadership change aims to enhance the company's financial oversight.